About the Office of HIV and AIDS Malignancy
The National Cancer Institute (NCI) established the Office of HIV and AIDS Malignancy (OHAM) in the Office of the Director in December 2007 to enhance its research effort in the field of HIV/AIDS and HIV malignancies. OHAM is led by Dr. Robert Yarchoan.
OHAM was created to:
- Provide broad oversight for HIV/AIDS research within and supported by NCI
- Facilitate NCI-wide coordination and prioritization of this effort
- Manage certain HIV/AIDS-specific research activities
- Act as a point of contact with the NIH Office of AIDS Research (OAR) and other Institutes and Centers
OHAM includes two Programs:
- The AIDS Malignancy Program
Led by Dr. Geraldina Dominguez, the AIDS Malignancy Program (AMP) has the primary responsibility for identifying new initiatives, for international activities, such as the initiative to Strengthen Capacity for HIV-Associated Malignancy Research in Africa, and for overseeing programs that the NCI co-manages with other Institutes, such as the Centers for AIDS Research (CFARs), the Multicenter AIDS Cohort Study (MACS), and the Women's Interagency HIV Study.
- The AIDS Cancer Clinical Program
Led by Dr. Mostafa Nokta, the AIDS Cancer Clinical Program (ACCP) has the primary responsibility for overseeing clinical programs in OHAM, including the AIDS Malignancy Consortium (AMC) and the AIDS and Cancer Specimen Resource (ACSR).
The mission of the Office of HIV and AIDS Malignancy (OHAM) is to facilitate and provide broad oversight for HIV/AIDS and HIV malignancy research throughout the National Cancer Institute (NCI). OHAM works with the NCI Director, the NCI Divisions, and other Offices in the NCI in managing the HIV/AIDS and HIV malignancy research portfolio. OHAM coordinates and prioritizes NCI research in HIV/AIDS and HIV malignancy and, in addition, directly initiates and manages certain research programs. AIDS research is conducted throughout the National Institutes of Health (NIH), and OHAM interfaces with the Office of AIDS Research and other Institutes and Centers in the NIH to effectively coordinate this research effort.
The ultimate goal of the OHAM/NCI research effort is to effectively prevent, diagnose, and treat HIV/AIDS, HIV-associated malignancies, and other malignancies developing in individuals with HIV infection. HIV infection and HIV-associated malignancies have a profound impact throughout the world, and OHAM research accordingly has both a domestic and an international focus.
OHAM strives to optimize the use of research resources throughout the NCI to advance knowledge in HIV/AIDS and HIV malignancy. The aim of this effort is to effectively prevent, diagnose, and treat these conditions, both in the United States and throughout the rest of the world.